180 related articles for article (PubMed ID: 12367766)
1. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
Samani KK; Brazier M; Mathiot C; Kamel S; Jamart J; Jaubert J; Blanc M; Azaïs I; Facon T; Leleu X
Ann Hematol; 2005 Jan; 84(1):19-24. PubMed ID: 15338198
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios.
Carlson K; Larsson A; Simonsson B; Turesson I; Westin J; Ljunghall S
Eur J Haematol; 1999 May; 62(5):300-6. PubMed ID: 10359057
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
[TBL] [Abstract][Full Text] [Related]
6. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
Jakob C; Zavrski I; Heider U; Brux B; Eucker J; Langelotz C; Sinha P; Possinger K; Sezer O
Eur J Haematol; 2002 Jul; 69(1):37-42. PubMed ID: 12270060
[TBL] [Abstract][Full Text] [Related]
7. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
9. Relationship of bone turnover to bone density and fractures.
Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients.
Maeno Y; Inaba M; Okuno S; Yamakawa T; Ishimura E; Nishizawa Y
Clin Chem; 2005 Dec; 51(12):2312-7. PubMed ID: 16223890
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
12. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
13. Urinary deoxypyridinoline excretion for the evaluation of bone turnover in chronic renal failure.
Coen G; Mantella D; Calabria S; Sardella D; Manni M; Fassino V; D'Anello E; Giustini M; Taggi F
Am J Nephrol; 2000; 20(4):283-90. PubMed ID: 10970981
[TBL] [Abstract][Full Text] [Related]
14. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.
Tsuchida T; Ishimura E; Miki T; Matsumoto N; Naka H; Jono S; Inaba M; Nishizawa Y
Osteoporos Int; 2005 Feb; 16(2):172-9. PubMed ID: 15164161
[TBL] [Abstract][Full Text] [Related]
15. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
[TBL] [Abstract][Full Text] [Related]
16. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy.
Abildgaard N; Brixen K; Kristensen JE; Eriksen EF; Nielsen JL; Heickendorff L
Br J Haematol; 2003 Jan; 120(2):235-42. PubMed ID: 12542480
[TBL] [Abstract][Full Text] [Related]
17. Bone metabolism during the perimenopausal transition: a prospective study.
Seifert-Klauss V; Mueller JE; Luppa P; Probst R; Wilker J; Höss C; Treumann T; Kastner C; Ulm K
Maturitas; 2002 Jan; 41(1):23-33. PubMed ID: 11809340
[TBL] [Abstract][Full Text] [Related]
18. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment.
Spagnoli A; Branca F; Spadoni GL; Cianfarani S; Pasquino AM; Argirò G; Vitale S; Robins SP; Boscherini B
J Clin Endocrinol Metab; 1996 Oct; 81(10):3589-93. PubMed ID: 8855806
[TBL] [Abstract][Full Text] [Related]
19. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
